<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Myelodysplastic | Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Myelodysplastic Syndromes (MDS)  Definition: A group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, resulting in cytopenias (anemia,...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Myelodysplastic | Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Myelodysplastic Syndromes (MDS)  Definition: A group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, resulting in cytopenias (anemia,...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Myelodysplastic | Hematology">
<meta name="twitter:description" content="Overview of Myelodysplastic Syndromes (MDS)  Definition: A group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, resulting in cytopenias (anemia,...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><meta name="google-adsense-account" content="ca-pub-1344282930858290">
<script async src="https://www.googletagmanager.com/gtag/js?id=G-JERRQQFPF4"></script><script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-JERRQQFPF4');
    </script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li><a class="" href="content-areas.html">Content Areas</a></li>
<li><a class="" href="author.html">Author</a></li>
<li><a class="" href="ascp-boc.html">ASCP BOC</a></li>
<li><a class="" href="reading-list.html">Reading List</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="active" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Laboratory</li>
<li><a class="" href="cell-counts.html">Cell Counts</a></li>
<li><a class="" href="manual.html">Manual</a></li>
<li><a class="" href="automated.html">Automated</a></li>
<li><a class="" href="retics.html">Retics</a></li>
<li><a class="" href="differentials.html">Differentials</a></li>
<li><a class="" href="morphologies.html">Morphologies</a></li>
<li><a class="" href="hemoglobin.html">Hemoglobin</a></li>
<li><a class="" href="quantitative-1.html">Quantitative</a></li>
<li><a class="" href="qualitative-1.html">Qualitative</a></li>
<li><a class="" href="electrophoresis.html">Electrophoresis</a></li>
<li><a class="" href="hplc.html">HPLC</a></li>
<li><a class="" href="sickle-solubility.html">Sickle Solubility</a></li>
<li><a class="" href="hematocrit.html">Hematocrit</a></li>
<li><a class="" href="indices.html">Indices</a></li>
<li><a class="" href="hemolysis.html">Hemolysis</a></li>
<li><a class="" href="special-stains.html">Special Stains</a></li>
<li><a class="" href="other-studies.html">Other Studies</a></li>
<li><a class="" href="esr.html">ESR</a></li>
<li><a class="" href="g6pd.html">G6PD</a></li>
<li><a class="" href="heinz-body.html">Heinz Body</a></li>
<li><a class="" href="flow-cytometry.html">Flow Cytometry</a></li>
<li><a class="" href="leukemia.html">Leukemia</a></li>
<li><a class="" href="lymphoma.html">Lymphoma</a></li>
<li><a class="" href="lymphocyte-subsets.html">Lymphocyte Subsets</a></li>
<li><a class="" href="pnh.html">PNH</a></li>
<li><a class="" href="molecularcytogenetic.html">Molecular/Cytogenetic</a></li>
<li><a class="" href="recurring-abnormalities.html">Recurring Abnormalities</a></li>
<li><a class="" href="bcrabl1.html">BCR/ABL1</a></li>
<li><a class="" href="jak2.html">JAK2</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary-1.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
<li><a class="" href="laboratory.html">Laboratory</a></li>
<li><a class="" href="ptinr.html">PT/INR</a></li>
<li><a class="" href="aptt.html">APTT</a></li>
<li><a class="" href="fibrinogen.html">Fibrinogen</a></li>
<li><a class="" href="d-dimer.html">D-dimer</a></li>
<li><a class="" href="thrombin-time.html">Thrombin Time</a></li>
<li><a class="" href="mixing-studies-1.html">Mixing Studies</a></li>
<li><a class="" href="factor-assays.html">Factor Assays</a></li>
<li><a class="" href="inhibitor-assays.html">Inhibitor Assays</a></li>
<li><a class="" href="von-willebrand-assays.html">von Willebrand Assays</a></li>
<li><a class="" href="platelet-function.html">Platelet Function</a></li>
<li><a class="" href="platelet-aggregation.html">Platelet Aggregation</a></li>
<li><a class="" href="thromboelastography.html">Thromboelastography</a></li>
<li><a class="" href="hypercoagulability.html">Hypercoagulability</a></li>
<li><a class="" href="assays.html">Assays</a></li>
<li><a class="" href="antiphospholipids.html">Antiphospholipids</a></li>
<li><a class="" href="protein-c.html">Protein C</a></li>
<li><a class="" href="protein-s.html">Protein S</a></li>
<li><a class="" href="molecular.html">Molecular</a></li>
<li><a class="" href="fv-leiden.html">FV Leiden</a></li>
<li><a class="" href="pt-20210.html">PT 20210</a></li>
<li><a class="" href="anti-xa.html">Anti-Xa</a></li>
<li><a class="" href="thrombin-inhibitors.html">Thrombin Inhibitors</a></li>
<li><a class="" href="heparin-neutralization.html">Heparin Neutralization</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Microbiology/blob">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="myelodysplastic" class="section level1 unnumbered">
<h1>Myelodysplastic<a class="anchor" aria-label="anchor" href="#myelodysplastic"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-myelodysplastic-syndromes-mds" class="section level2 unnumbered">
<h2>
<strong>Overview of Myelodysplastic Syndromes (MDS)</strong><a class="anchor" aria-label="anchor" href="#overview-of-myelodysplastic-syndromes-mds"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A group of clonal hematopoietic stem cell disorders characterized by <em>ineffective hematopoiesis,</em> resulting in cytopenias (anemia, thrombocytopenia, and/or neutropenia) and a variable risk of transformation to acute myeloid leukemia (AML)</li>
<li>
<strong>Key Features:</strong>
<ul>
<li>Dysplasia: Abnormal morphology and maturation of hematopoietic cells in the bone marrow</li>
<li>Ineffective Hematopoiesis: Increased apoptosis (programmed cell death) of hematopoietic precursors in the bone marrow, leading to decreased production of mature blood cells</li>
<li>Cytopenias: One or more peripheral blood cytopenias (anemia, thrombocytopenia, and/or neutropenia)</li>
<li>Risk of Transformation: Variable risk of progression to acute myeloid leukemia (AML)</li>
</ul>
</li>
<li>
<strong>Epidemiology:</strong> Primarily affects older adults (median age at diagnosis is &gt;65 years)</li>
<li>
<strong>Etiology:</strong>
<ul>
<li>Most cases are <em>de novo</em> (arising without a known cause)</li>
<li>Some cases are therapy-related (t-MDS), occurring after exposure to cytotoxic chemotherapy or radiation therapy</li>
<li>Genetic predisposition plays a role in a small number of cases</li>
</ul>
</li>
</ul>
</div>
<div id="pathophysiology-4" class="section level2 unnumbered">
<h2>
<strong>Pathophysiology</strong><a class="anchor" aria-label="anchor" href="#pathophysiology-4"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Clonal Hematopoiesis:</strong> MDS arises from a mutated hematopoietic stem cell that has a proliferative advantage over normal stem cells</li>
<li>
<strong>Genetic Mutations:</strong> Acquired mutations in genes involved in:
<ul>
<li>Splicing factors (e.g., <em>SF3B1</em>, <em>SRSF2</em>, <em>U2AF1</em>)</li>
<li>DNA methylation (e.g., <em>TET2</em>, <em>DNMT3A</em>)</li>
<li>Transcription factors (e.g., <em>RUNX1</em>, <em>TP53</em>)</li>
<li>Signaling pathways (e.g., <em>RAS</em> pathway)</li>
</ul>
</li>
<li>
<strong>Impaired Differentiation:</strong> Mutations disrupt normal differentiation and maturation of hematopoietic cells</li>
<li>
<strong>Dysplasia:</strong> Abnormal morphological features in one or more cell lines (erythroid, myeloid, megakaryocytic)</li>
<li>
<strong>Increased Apoptosis:</strong> Dysplastic cells are prone to apoptosis (programmed cell death) in the bone marrow, contributing to ineffective hematopoiesis</li>
<li>
<strong>Cytokine Dysregulation:</strong> Abnormal production of cytokines by bone marrow cells can contribute to ineffective hematopoiesis and cytopenias</li>
<li>
<strong>Immune Dysregulation:</strong> Abnormal immune responses may contribute to bone marrow failure in some cases</li>
</ul>
</div>
<div id="who-classification-of-mds-2016-revision" class="section level2 unnumbered">
<h2>
<strong>WHO Classification of MDS (2016 Revision)</strong><a class="anchor" aria-label="anchor" href="#who-classification-of-mds-2016-revision"><i class="fas fa-link"></i></a>
</h2>
<p>The World Health Organization (WHO) classification is used to categorize MDS based on:</p>
<ul>
<li>
<strong>Morphological Features:</strong> Dysplasia in one or more cell lines, blast percentage</li>
<li>
<strong>Cytogenetic Abnormalities:</strong> Specific chromosomal abnormalities</li>
<li>
<strong>Blast Percentage:</strong> Percentage of blasts in the bone marrow and peripheral blood</li>
</ul>
<p>Key Subtypes of MDS:</p>
<ul>
<li>
<strong>MDS with Single Lineage Dysplasia (MDS-SLD):</strong>
<ul>
<li>Cytopenia in one cell line (anemia, thrombocytopenia, or neutropenia)</li>
<li>Dysplasia in one cell line only</li>
<li>&lt;5% blasts in the bone marrow and &lt;1% blasts in the peripheral blood</li>
</ul>
</li>
<li>
<strong>MDS with Ring Sideroblasts (MDS-RS):</strong>
<ul>
<li>Subclassified as:
<ul>
<li>
<strong>MDS-RS-SLD:</strong> Single lineage dysplasia with ≥15% ring sideroblasts in the bone marrow</li>
<li>
<strong>MDS-RS-MLD:</strong> Multilineage dysplasia with ≥15% ring sideroblasts in the bone marrow</li>
</ul>
</li>
<li>Cytopenia in one or more cell lines</li>
<li>&lt;5% blasts in the bone marrow and &lt;1% blasts in the peripheral blood</li>
<li>Often associated with <em>SF3B1</em> mutation</li>
</ul>
</li>
<li>
<strong>MDS with Multilineage Dysplasia (MDS-MLD):</strong>
<ul>
<li>Cytopenia in one or more cell lines</li>
<li>Dysplasia in ≥50% of cells in at least two cell lines</li>
<li>&lt;5% blasts in the bone marrow and &lt;1% blasts in the peripheral blood</li>
</ul>
</li>
<li>
<strong>MDS with Excess Blasts (MDS-EB):</strong>
<ul>
<li>Subclassified as:
<ul>
<li>
<strong>MDS-EB-1:</strong> 5-9% blasts in the bone marrow or 2-4% blasts in the peripheral blood</li>
<li>
<strong>MDS-EB-2:</strong> 10-19% blasts in the bone marrow or 5-9% blasts in the peripheral blood</li>
</ul>
</li>
<li>Cytopenias in one or more cell lines</li>
<li>May have Auer rods</li>
</ul>
</li>
<li>
<strong>MDS with Isolated del(5q):</strong>
<ul>
<li>Anemia</li>
<li>Normal or increased platelet count</li>
<li>&lt;5% blasts in the bone marrow and &lt;1% blasts in the peripheral blood</li>
<li>Isolated del(5q) cytogenetic abnormality</li>
<li>Often responsive to lenalidomide</li>
</ul>
</li>
</ul>
</div>
<div id="clinical-manifestations-5" class="section level2 unnumbered">
<h2>
<strong>Clinical Manifestations</strong><a class="anchor" aria-label="anchor" href="#clinical-manifestations-5"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p><strong>Symptoms of Cytopenias:</strong></p>
<ul>
<li>Anemia: Fatigue, weakness, pallor, shortness of breath</li>
<li>Thrombocytopenia: Bleeding, bruising, petechiae (small, pinpoint hemorrhages)</li>
<li>Neutropenia: Increased susceptibility to infections</li>
</ul>
</li>
<li>
<p><strong>Other Symptoms:</strong></p>
<ul>
<li>Some patients are asymptomatic and MDS is found incidentally in the blood test</li>
<li>Splenomegaly (enlarged spleen): Less common than in myeloproliferative neoplasms</li>
<li>Hepatosplenomegaly (enlarged liver and spleen)</li>
<li>Systemic Symptoms (Less Common): Fever, weight loss, night sweats</li>
</ul>
</li>
</ul>
</div>
<div id="laboratory-findings-4" class="section level2 unnumbered">
<h2>
<strong>Laboratory Findings</strong><a class="anchor" aria-label="anchor" href="#laboratory-findings-4"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p><strong>Complete Blood Count (CBC):</strong></p>
<ul>
<li>Cytopenias in one or more cell lines (anemia, thrombocytopenia, neutropenia)
<ul>
<li>May see macrocytosis (increased MCV) or dimorphic RBC population</li>
</ul>
</li>
<li>Variable WBC count (may be low, normal, or high)</li>
<li>Presence of blasts in the peripheral blood (variable, depends on the subtype of MDS)</li>
</ul>
</li>
<li>
<p><strong>Peripheral Blood Smear:</strong></p>
<ul>
<li>Dysplastic Features in One or More Cell Lines:
<ul>
<li>RBCs: Oval macrocytes, hypochromia, basophilic stippling, Howell-Jolly bodies, teardrop cells</li>
<li>Neutrophils: Pseudo-Pelger-Huët anomaly (bilobed or unsegmented neutrophils), hypogranulation, abnormal nuclear segmentation</li>
<li>Platelets: Large platelets, abnormal granulation</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Reticulocyte Count:</strong></p>
<ul>
<li>Low or Normal (inappropriately low for the degree of anemia)</li>
</ul>
</li>
<li>
<p><strong>Bone Marrow Aspiration and Biopsy:</strong></p>
<ul>
<li>Increased Cellularity (Hypercellular) or Decreased Cellularity (Hypocellular)</li>
<li>Dysplasia in One or More Cell Lines:
<ul>
<li>Erythroid dysplasia: Multinucleated erythroid precursors, nuclear budding, megaloblastoid changes</li>
<li>Myeloid dysplasia: Abnormal nuclear segmentation, hypogranulation, Auer rods (rare)</li>
<li>Megakaryocytic dysplasia: Micromegakaryocytes, hypolobated megakaryocytes</li>
</ul>
</li>
<li>Increased Blast Percentage: Used to classify MDS subtypes</li>
<li>Ring Sideroblasts: Erythroid precursors with iron-laden mitochondria encircling the nucleus (≥15% ring sideroblasts in MDS-RS subtypes)</li>
</ul>
</li>
<li>
<p><strong>Cytogenetic Analysis:</strong></p>
<ul>
<li>Chromosomal Abnormalities are Common in MDS
<ul>
<li>del(5q): Seen in MDS with isolated del(5q)</li>
<li>Trisomy 8 (+8)</li>
<li>del(20q)</li>
<li>del(7q) or monosomy 7 (-7)</li>
<li>Complex Karyotype: Presence of multiple cytogenetic abnormalities; associated with poor prognosis</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Flow Cytometry Immunophenotyping:</strong></p>
<ul>
<li>To Identify Abnormal Cell Populations and Assess for Dysplasia
<ul>
<li>Aberrant expression of cell surface markers</li>
<li>Abnormal cell ratios</li>
<li>Helps differentiate MDS from other conditions</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Molecular Testing:</strong></p>
<ul>
<li>To Detect Gene Mutations that are Important for Diagnosis, Prognosis, and Treatment Planning
<ul>
<li>Commonly Mutated Genes:
<ul>
<li>
<em>SF3B1</em> (splicing factor)</li>
<li>
<em>TET2</em> (DNA methylation)</li>
<li>
<em>DNMT3A</em> (DNA methylation)</li>
<li>
<em>ASXL1</em> (chromatin modifier)</li>
<li>
<em>RUNX1</em> (transcription factor)</li>
<li>
<em>TP53</em> (tumor suppressor)</li>
<li>
<em>EZH2</em> (chromatin modifier)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="diagnostic-criteria" class="section level2 unnumbered">
<h2>
<strong>Diagnostic Criteria</strong><a class="anchor" aria-label="anchor" href="#diagnostic-criteria"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>Presence of One or More Cytopenias (Anemia, Thrombocytopenia, and/or Neutropenia)</li>
<li>Dysplasia in at least One Cell Line (Erythroid, Myeloid, or Megakaryocytic) in the Bone Marrow</li>
<li>Blast Percentage in the Bone Marrow is &lt;20%</li>
<li>Absence of Other Myeloid Neoplasms (e.g., CML, AML with recurrent genetic abnormalities)</li>
<li>Cytogenetic Abnormalities - Helpful for Classification and Prognosis</li>
</ul>
</div>
<div id="prognostic-scoring-systems" class="section level2 unnumbered">
<h2>
<strong>Prognostic Scoring Systems</strong><a class="anchor" aria-label="anchor" href="#prognostic-scoring-systems"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Revised International Prognostic Scoring System (IPSS-R):</strong>
<ul>
<li>Used to estimate the prognosis and risk of AML transformation in patients with MDS</li>
<li>Based on:
<ul>
<li>Percentage of blasts in the bone marrow</li>
<li>Cytogenetic abnormalities</li>
<li>Number of cytopenias</li>
<li>Assigns patients to risk categories: Very low, low, intermediate, high, or very high</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="treatment-and-management-4" class="section level2 unnumbered">
<h2>
<strong>Treatment and Management</strong><a class="anchor" aria-label="anchor" href="#treatment-and-management-4"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p><strong>Goals of Treatment:</strong></p>
<ul>
<li>Improve blood counts</li>
<li>Reduce the risk of infections and bleeding</li>
<li>Delay or prevent transformation to AML</li>
<li>Improve quality of life and survival</li>
</ul>
</li>
<li>
<p><strong>Treatment Options:</strong></p>
<ul>
<li>Supportive Care:
<ul>
<li>Transfusions (RBCs and platelets) to manage anemia and thrombocytopenia</li>
<li>Growth factors (e.g., erythropoietin, G-CSF) to stimulate blood cell production</li>
<li>Antibiotics to treat infections</li>
<li>Iron chelation therapy to manage iron overload from chronic transfusions (if needed)</li>
</ul>
</li>
<li>Hypomethylating Agents (HMAs):
<ul>
<li>Azacitidine and decitabine</li>
<li>Inhibit DNA methylation, leading to improved hematopoiesis and reduced risk of AML transformation</li>
<li>Used in higher-risk MDS</li>
</ul>
</li>
<li>Lenalidomide:
<ul>
<li>An immunomodulatory drug used for patients with MDS with deletion 5q</li>
<li>Effective in reducing transfusion dependence and improving cytopenias</li>
</ul>
</li>
<li>Luspatercept:
<ul>
<li>A recombinant fusion protein that binds to TGF-β superfamily ligands</li>
<li>Promotes erythroid maturation and reduces transfusion burden in patients with MDS-RS</li>
</ul>
</li>
<li>Hematopoietic Stem Cell Transplantation (HSCT):
<ul>
<li>Potentially curative option, especially for younger patients with high-risk MDS</li>
<li>Involves replacing the patient’s damaged bone marrow with healthy stem cells from a donor</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="key-terms-27" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-27"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Myelodysplastic Syndromes (MDS):</strong> Clonal hematopoietic stem cell disorders with ineffective hematopoiesis and dysplasia</li>
<li>
<strong>Dysplasia:</strong> Abnormal cell development or maturation</li>
<li>
<strong>Cytopenia:</strong> Deficiency of blood cells (e.g., anemia, neutropenia, thrombocytopenia)</li>
<li>
<strong>Ring Sideroblasts:</strong> Erythroid precursors with iron-laden mitochondria encircling the nucleus</li>
<li>
<strong>Refractory Anemia:</strong> Anemia that does not respond to standard treatments</li>
<li>
<strong>Hypomethylating Agents:</strong> Drugs that inhibit DNA methylation</li>
<li>
<strong>Hematopoietic Stem Cell Transplantation (HSCT):</strong> Procedure to replace damaged bone marrow with healthy stem cells</li>
</ul>
</div>
</div>
<!-- Scoll to TOC element -->
<script defer>
  // adjust TOC scroll to selected element/topic
  function scroll_to_element() {
    header_height = document.getElementsByTagName('header')[0].offsetHeight/2;
    toc_element_position = document.querySelector('.book-toc > li > a.active').offsetTop;
    if(document.querySelector('.book-toc > li > a.active').offsetLeft == 0) {
      toc_element_position1 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetTop;
      toc_element_position2 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetHeight;
      toc_element_position = toc_element_position1 + toc_element_position2;
    }
    document.getElementsByTagName('header')[0].scrollTo(0, toc_element_position - header_height, 'smooth');
  }
  window.onload = scroll_to_element();

  // hide those labes that take up multiple lines
  l = [];
  function hide_label() {
    document
      .querySelectorAll('.book-toc > li')
      .forEach(elem => {
        window
          .getComputedStyle(elem)
          .textTransform === "uppercase"
          &&
          !elem.classList
          .contains('book-part')
          ? l.push(elem)
          : '';
      });
  }
  hide_label();
  head = document.getElementsByTagName('header')[0];
  head.addEventListener('scroll', () => {
    count = 0;
    prev_elem = '';
    l.forEach((elem) => {
      if(count === 0) {
        initial_y = elem.getBoundingClientRect().y + 20;
        count = 1;
      } else {
        if(elem.getBoundingClientRect().y < initial_y) {
          prev_elem.classList.add('hide_label');
        } else {
          prev_elem.classList.remove('hide_label');
        }
      }
      prev_elem = elem;
    });
  });
</script><div class="chapter-nav">
<div class="prev"><a href="aml.html">AML</a></div>
<div class="next"><a href="myeloproliferative.html">Myeloproliferative</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#myelodysplastic">Myelodysplastic</a></li>
<li><a class="nav-link" href="#overview-of-myelodysplastic-syndromes-mds">Overview of Myelodysplastic Syndromes (MDS)</a></li>
<li><a class="nav-link" href="#pathophysiology-4">Pathophysiology</a></li>
<li><a class="nav-link" href="#who-classification-of-mds-2016-revision">WHO Classification of MDS (2016 Revision)</a></li>
<li><a class="nav-link" href="#clinical-manifestations-5">Clinical Manifestations</a></li>
<li><a class="nav-link" href="#laboratory-findings-4">Laboratory Findings</a></li>
<li><a class="nav-link" href="#diagnostic-criteria">Diagnostic Criteria</a></li>
<li><a class="nav-link" href="#prognostic-scoring-systems">Prognostic Scoring Systems</a></li>
<li><a class="nav-link" href="#treatment-and-management-4">Treatment and Management</a></li>
<li><a class="nav-link" href="#key-terms-27">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Microbiology/blob/blob/main/Rmd/02-09-leukocyte-neoplasia-myeloid-mds.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Microbiology/blob/edit/main/Rmd/02-09-leukocyte-neoplasia-myeloid-mds.Rmd" target="_blank">Edit this page <i class="fab fa-github"></i></a></li>
          <li><a id="buymeacoffee" href="https://buymeacoffee.com/bloodcellid" target="_blank">NEED Caffeine</a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->


</body>
</html>
